Home › Trial NCT07730125
Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies
- Trial IDNCT07730125
- StatusNot Yet Recruiting
- PhasePhase 1/2
- Study typeInterventional
- SponsorCoRegen, Inc.
- Enrollment67
- Start date2026-11
- ConditionsHR-positive, HER2-negative Breast Cancer · TNBC - Triple-Negative Breast Cancer · Prostate Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.